Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing–Remitting Multiple Sclerosis. - Costa-Frossard, Lucienne; Brieva, Luis; García-Estévez, Daniel Apolinar; Martín-Martínez, Jesús Manuel; Álvarez-Bravo, Gary; Blasco-Quílez, María Rosario; Meca-Lallana, José E.; Calles-Hernández, María Carmen; Ramo Tello, Cristina; Muñoz-Fernández, Carmen; Barbero, David Enrique; López-Muñoz, Pablo; et al. (International Journal of Molecular Sciences, 2026)